Maravai Lifesciences Holdings, Inc. SEC filings MRVI
Maravai Lifesciences Holdings, Inc. has 425 filings in SEC EDGAR's recent list, going back to Sep 8, 2020. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-K | Filing | Mar 4, 2025 | Mar 4, 2025 |
| UPLOAD | Letter from the SEC | Feb 20, 2025 | — |
| CORRESP | Letter to the SEC | Feb 19, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2024 | — |
| CORRESP | Letter to the SEC | Aug 16, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2024 | — |
| CORRESP | Letter to the SEC | Jun 24, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 28, 2022 | — |
| CORRESP | Letter to the SEC | Jul 12, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 29, 2022 | — |
| EFFECT | Filing | Sep 9, 2021 | — |
| CORRESP | Letter to the SEC | Sep 7, 2021 | — |
| CORRESP | Letter to the SEC | Sep 7, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 31, 2021 | — |
| DRS | Filing | Aug 26, 2021 | — |
| EFFECT | Filing | Apr 7, 2021 | — |
| CORRESP | Letter to the SEC | Apr 5, 2021 | — |
| CORRESP | Letter to the SEC | Apr 5, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2021 | — |
| DRS | Filing | Mar 25, 2021 | — |
| EFFECT | Filing | Nov 19, 2020 | — |
| CERT | 8a cert | Nov 19, 2020 | — |
| 8-A12B | Filing | Nov 19, 2020 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| CORRESP | Letter to the SEC | Nov 16, 2020 | — |
| CORRESP | Letter to the SEC | Nov 9, 2020 | — |
| CORRESP | Letter to the SEC | Nov 6, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2020 | — |
| CORRESP | Letter to the SEC | Oct 29, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2020 | — |
| DRSLTR | Filing | Oct 23, 2020 | — |
| DRS/A | Filing | Oct 23, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 21, 2020 | — |
| DRSLTR | Filing | Oct 14, 2020 | — |
| DRS/A | Filing | Oct 14, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 8, 2020 | — |
| DRS | Filing | Sep 8, 2020 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1823239
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.